BEAM-302: Beam’s lead genetic disease program is BEAM-302, a potentially best-in-class liver-targeting LNP formulation of base editing reagents designed to correct the PiZ allele, the most ...
"LNPs have achieved significant success for non-viral gene delivery, particularly in COVID-19 vaccines, but not much has been known about how the LNP structure affects bioactivity," said HighField CEO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback